Literature DB >> 32697930

Therapeutic choices in persons with haemophilia at the time of COVID-19.

Antonio Coppola1, Federica Riccardi1, Annarita Tagliaferri1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32697930      PMCID： PMC7375889          DOI： 10.2450/2020.0154-20

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  5 in total

1.  Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.

Authors:  Annarita Tagliaferri; Annalisa Matichecchia; Gianna F Rivolta; Federica Riccardi; Gabriele Quintavalle; Anna Benegiamo; Rossana Rossi; Antonio Coppola
Journal:  Blood Transfus       Date:  2019-11-04       Impact factor: 3.443

2.  Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures.

Authors:  Isabella McCary; Christine Guelcher; Jan Kuhn; Regina Butler; Gita Massey; Michael F Guerrera; Lance Ballester; Leslie Raffini
Journal:  Haemophilia       Date:  2020-04-20       Impact factor: 4.287

3.  The COVID-19 pandemic: New global challenges for the haemophilia community.

Authors:  Cedric Hermans; Alain Weill; Glenn F Pierce
Journal:  Haemophilia       Date:  2020-04-20       Impact factor: 4.287

4.  Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis.

Authors:  Cedric Hermans; Catherine Lambert
Journal:  J Thromb Haemost       Date:  2020-05-11       Impact factor: 5.824

Review 5.  Hemophilia therapy: the future has begun.

Authors:  Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2020-02-14       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.